Potent and selective inhibitors of Nav1.7

US10344060B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Justin K. MURRAY · Madison, US
• Jerry Ryan HOLDER · Simi Valley, US
• Malgorzata Wanska · Camarillo, US
• Christopher M. Tegley · Thousand Oaks, US
• James R. Falsey · Moorpark, US
• Elizabeth M. Doherty · Thousand Oaks, US
• Leslie P. Miranda · Thousand Oaks, US
• Kaustav Biswas · Thousand Oaks, US
• Bin Wu · Thousand Oaks, US
• Kelvin Sham · Thousand Oaks, US
• Jason C. LONG · Newbury Park, US

Key dates

• Filing date: Mar 12, 2014
• Grant date: Jul 9, 2019
• Expiry date: Mar 12, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/47
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.